

# Katharine L Lewis

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7443873/publications.pdf>

Version: 2024-02-01

15  
papers

410  
citations

1307594

7  
h-index

1125743

13  
g-index

15  
all docs

15  
docs citations

15  
times ranked

338  
citing authors

#	ARTICLE	IF	CITATIONS
1	Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study. <i>Lancet</i> , The, 2021, 397, 892-901.	13.7	260
2	Timing of high-dose methotrexate CNS prophylaxis in DLBCL: a multicenter international analysis of 1384 patients. <i>Blood</i> , 2022, 139, 2499-2511.	1.4	42
3	Ibrutinib for central nervous system lymphoma: the Australasian Lymphoma Alliance/MD Anderson Cancer Center experience. <i>British Journal of Haematology</i> , 2021, 192, 1049-1053.	2.5	31
4	Non-Covalent BTK Inhibitorsâ€”The New BTKids on the Block for B-Cell Malignancies. <i>Journal of Personalized Medicine</i> , 2021, 11, 764.	2.5	30
5	New Directions for Mantle Cell Lymphoma in 2022. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2022, 42, 614-628.	3.8	14
6	Pirtobrutinib, A Next Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated Mantle Cell Lymphoma: Updated Results from the Phase 1/2 BRUIN Study. <i>Blood</i> , 2021, 138, 381-381.	1.4	8
7	Autologous stem cell transplantation for untreated transformed indolent Bâ€cell lymphoma in first remission: an international, multiâ€centre propensityâ€scoreâ€matched study. <i>British Journal of Haematology</i> , 2020, 191, 806-815.	2.5	7
8	LOXO-305, A Next Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated Mantle Cell Lymphoma, WaldenstrÃ¶m's Macroglobulinemia, and Other Non-Hodgkin Lymphomas: Results from the Phase 1/2 BRUIN Study. <i>Blood</i> , 2020, 136, 8-10.	1.4	5
9	Refractory $\hat{1}\hat{2}$ -Hepatosplenic T-cell Lymphoma With Secondary CNS Dissemination and Severe Morbidity Related to Intrathecal Chemotherapy: A Case Report and Literature Review. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e564-e567.	0.4	4
10	The Selective Bruton Tyrosine Kinase (BTK) Inhibitor TG-1701 As Monotherapy and in Combination with Ublituximab and Umbralisib (U2) in Patients with B-Cell Malignancies. <i>Blood</i> , 2021, 138, 1549-1549.	1.4	4
11	Systemic ALCL Treated in Routine Clinical Practice: Outcomes Following First-Line Chemotherapy from a Multicentre Cohort. <i>Advances in Therapy</i> , 2021, 38, 3789-3802.	2.9	3
12	Updated results of the selective Bruton tyrosine kinase (BTK) inhibitor TG-1701, as monotherapy and in combination with ublituximab and umbralisib (U2) in patients (pts) with B-cell malignancies.. <i>Journal of Clinical Oncology</i> , 2021, 39, 7525-7525.	1.6	1
13	Abstract CT138: Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in combination with venetoclax $\hat{1}\hat{2}$ rituximab in relapsed/refractory chronic lymphocytic leukemia: Results from the BRUIN phase 1b study. <i>Cancer Research</i> , 2022, 82, CT138-CT138.	0.9	1
14	Event free survival at 12 months (EFS12) in stage 1 DLBCL â€“ a reassuring milestone?. <i>Leukemia and Lymphoma</i> , 2020, 61, 2542-2543.	1.3	0
15	Autologous stem cell transplantation for untreated transformed indolent B-cell lymphoma in first remission: An international, multicenter propensity matched study.. <i>Journal of Clinical Oncology</i> , 2020, 38, 8021-8021.	1.6	0